Motivations and practice-area preferences of pharmacists interested in pursuing a Pharm.D. degree through a nontraditional program.

Pharmacists' interest in a proposed nontraditional Pharm.D. program, motivations for wanting to pursue a Pharm.D. degree, and practice-area preferences were surveyed. Questionnaires were mailed to 12,621 pharmacists in Illinois and Arizona. Information sought included current position and practice area, number of job and career changes, preferred practice area, and interest in enrolling in a proposed nontraditional Pharm.D. program described in a cover letter. For pharmacists indicating an interest, information was sought on motivations for wanting to pursue a Pharm.D. degree expected support from employers, and preferred practice areas after obtaining a Pharm.D. degree. The response rate was 28.8%. A total of 1119 respondents (31.9%) indicated that they would or probably would enroll in the proposed Pharm.D. program. These pharmacists gave improving their clinical skills and improving the quality of their work as reasons for wanting to enroll, and half indicated that their current practice area would be their preferred area after they completed a Pharm.D. degree. Almost three quarters (72%) of hospital pharmacists; more than 60% of home health care or consultant independent, and managed care pharmacists; and 21% of pharmacists in chain pharmacies stated a preference to stay in their current practice area after obtaining a Pharm.D. degree. Eight variables were useful in predicting whether respondents would prefer to remain in their current practice area, including tuition assistance or reimbursement from employers, satisfaction with current position, and number of years in current position. Respondents who were interested in pursuing a Pharm.D. degree through the nontraditional program described to them were motivated by a desire to improve their clinical skills and the quality of their work and the opportunity to open doors to new careers.

Points to consider about prescription drug prices: an overview of federal policy and pricing studies.

Pharmaceutical prices in the United States are under evaluation as policy makers decide how to reduce health care expenditures and public subsidy of the pharmaceutical industry. Furthermore, evidence of higher drug prices in the United States, compared with those in other countries, fuels the prescription drug price debate. These issues are not new to the public forum and much can be learned from prior debates and policies. This paper begins by reviewing the pricing debate with the Kefauver hearings on monopolies held during the late 1950s and early 1960s and continues with the current price debate. Government reports and academic studies are discussed, addressing the methodological differences and their implications to policy makers. Finally, the literature review includes foreign government prescription drug programs with their respective prescription drug expenditures. Evidence provided by academics about the pricing practices of the drug manufacturers indicates product quality and price information would force firms to compete on the price level, thus reducing pharmaceutical product pricing to the "true" market price.